Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM03 (anti-CD22 antibody) plus corticosteroids vs placebo plus corticosteroids in bullous pemphigoid
ChiCTR2600126872Phase 4Not yet recruiting
- Sponsor
- Shandong First Medical University Affiliated Dermatology Hospital
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in Bullous Pemphigoid (BP) comparing Control group: placebo plus corticosteroids with Experimental group: SM03 plus corticosteroids (2 arms). Primary endpoint: complete remission rate at week 52. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
suciraslimab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on ChiCTR2600126872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126872.